Suppr超能文献

CD117、BAP1、MTAP和TdT是用于区分胸腺瘤和胸腺癌的有用免疫组织化学检测组合。

CD117, BAP1, MTAP, and TdT Is a Useful Immunohistochemical Panel to Distinguish Thymoma from Thymic Carcinoma.

作者信息

Angirekula Mounika, Chang Sindy Y, Jenkins Sarah M, Greipp Patricia T, Sukov William R, Marks Randolph S, Olivier Kenneth R, Cassivi Stephen D, Roden Anja C

机构信息

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55902, USA.

Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN 55902, USA.

出版信息

Cancers (Basel). 2022 May 5;14(9):2299. doi: 10.3390/cancers14092299.

Abstract

BACKGROUND

The morphologic distinction between thymic carcinomas and thymomas, specifically types B3, A, and occasionally micronodular thymomas with lymphoid stroma (MNTLS) can be challenging, as has also been shown in interobserver reproducibility studies. Since thymic carcinomas have a worse prognosis than thymomas, the diagnosis is important for patient management and treatment. This study aimed to identify a panel of immunohistochemical (IHC) markers that aid in the distinction between thymomas and thymic carcinomas in routine practice.

MATERIALS AND METHOD

Thymic carcinomas, type A and B3 thymomas, and MNTLS were identified in an institutional database of thymic epithelial tumors (TET) (1963-2021). IHC was performed using antibodies against TdT, Glut-1, CD5, CD117, BAP1, and mTAP. Percent tumor cell staining was recorded (Glut-1, CD5, CD117); loss of expression (BAP1, mTAP) was considered if essentially all tumor cells were negative; TdT was recorded as thymocytes present or absent (including rare thymocytes).

RESULTS

81 specimens included 44 thymomas (25 type A, 11 type B3, 8 MNTLS) and 37 thymic carcinomas (including 24 squamous cell carcinomas). Using BAP1, mTAP, CD117 (cut-off, 10%), and TdT, 88.9% of thymic carcinomas (95.7% of squamous cell carcinomas) and 77.8% of thymomas could be predicted. Glut-1 expression was not found to be useful in that distinction. All tumors that expressed CD5 in ≥50% of tumor cells also expressed CD117 in ≥10% of tumor cells. In four carcinomas with homozygous deletion of , mTAP expression was lost in two squamous cell carcinomas and in a subset of tumor cells of an adenocarcinoma and was preserved in a lymphoepithelial carcinoma.

CONCLUSION

A panel of immunostains including BAP1, mTAP, CD117 (using a cut-off of 10% tumor cell expression), and TdT can be useful in the distinction between thymomas and thymic carcinomas, with only a minority of cases being inconclusive.

摘要

背景

胸腺癌与胸腺瘤(特别是B3型、A型,偶尔还有伴淋巴样间质的微结节性胸腺瘤(MNTLS))之间的形态学区分可能具有挑战性,这在观察者间重复性研究中也得到了证实。由于胸腺癌的预后比胸腺瘤差,因此该诊断对患者的管理和治疗很重要。本研究旨在确定一组免疫组化(IHC)标志物,以帮助在常规实践中区分胸腺瘤和胸腺癌。

材料与方法

在一个胸腺上皮肿瘤(TET)的机构数据库(1963 - 2021年)中识别胸腺癌、A型和B3型胸腺瘤以及MNTLS。使用抗TdT、Glut-1、CD5、CD117、BAP1和mTAP的抗体进行免疫组化。记录肿瘤细胞染色百分比(Glut-1、CD5、CD117);如果基本上所有肿瘤细胞均为阴性,则认为存在表达缺失(BAP1、mTAP);记录TdT为胸腺细胞存在或不存在(包括罕见的胸腺细胞)。

结果

81个标本包括44个胸腺瘤(25个A型、11个B3型、8个MNTLS)和37个胸腺癌(包括24个鳞状细胞癌)。使用BAP1、mTAP、CD117(临界值为10%)和TdT,可以预测88.9%的胸腺癌(95.7%的鳞状细胞癌)和77.8%的胸腺瘤。未发现Glut-1表达在该区分中有用。所有肿瘤细胞中≥50%表达CD5的肿瘤,其肿瘤细胞中≥10%也表达CD117。在4个存在纯合缺失的癌中,mTAP表达在2个鳞状细胞癌以及1个腺癌的部分肿瘤细胞中缺失,而在1个淋巴上皮癌中保留。

结论

一组免疫染色,包括BAP1、mTAP、CD117(使用肿瘤细胞表达临界值10%)和TdT,可有助于区分胸腺瘤和胸腺癌,只有少数病例难以确定。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55fa/9100150/7441b492867c/cancers-14-02299-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验